NCT03289234View on ClinicalTrials.gov

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 16, 2016

Primary Completion Date

July 20, 2018

Study Completion Date

July 24, 2018

Conditions
Hepatic ImpairmentHealthy
Interventions
DRUG

MCI-186

30 mg of edaravone will be administered intravenously over 60 minutes

Trial Locations (2)

Unknown

Investigational site, Fukuoka

Investigational site, Tokyo

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY